AR081434A1 - Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo - Google Patents
Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpoInfo
- Publication number
- AR081434A1 AR081434A1 ARP110101867A ARP110101867A AR081434A1 AR 081434 A1 AR081434 A1 AR 081434A1 AR P110101867 A ARP110101867 A AR P110101867A AR P110101867 A ARP110101867 A AR P110101867A AR 081434 A1 AR081434 A1 AR 081434A1
- Authority
- AR
- Argentina
- Prior art keywords
- antibody
- anogen
- seq
- pain
- cgrp
- Prior art date
Links
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 title abstract 3
- 208000002193 Pain Diseases 0.000 title abstract 3
- 239000012634 fragment Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 102100025588 Calcitonin gene-related peptide 1 Human genes 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- BBBFJLBPOGFECG-UHFFFAOYSA-N salmon calcitonin Chemical compound C=1N=CNC=1CC(C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CCC(N)=O)C(=O)NC(C(C)O)C(=O)NC(CC=1C=CC(O)=CC=1)C(=O)N1C(CCC1)C(=O)NC(CCCNC(N)=N)C(=O)NC(C(C)O)C(=O)NC(CC(N)=O)C(=O)NC(C(C)O)C(=O)NCC(=O)NC(CO)C(=O)NCC(=O)NC(C(C)O)C(=O)N1C(CCC1)C(N)=O)NC(=O)C(CC(C)C)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(N)=O)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CCCCN)NC(=O)CNC(=O)C(CC(C)C)NC(=O)C(C(C)C)NC(=O)C1CSSCC(N)C(=O)NC(CO)C(=O)NC(CC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CO)C(=O)NC(C(C)O)C(=O)N1 BBBFJLBPOGFECG-UHFFFAOYSA-N 0.000 title 1
- 150000001413 amino acids Chemical group 0.000 abstract 2
- DNKYDHSONDSTNJ-XJVRLEFXSA-N chembl1910953 Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)N)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)C1=CN=CN1 DNKYDHSONDSTNJ-XJVRLEFXSA-N 0.000 abstract 2
- 102000004414 Calcitonin Gene-Related Peptide Human genes 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000010353 genetic engineering Methods 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57527—Calcitonin gene related peptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57545—Neuropeptide Y
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Zoology (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Anticuerpo del péptido relacionado con el gen calcitonina (CGRP) disenado por ingeniería genética humano que comprende una region variable de cadena ligera (LCVR) y una region variable de cadena pesada (HCVR) , en donde dicha LCVR comprende secuencias de aminoácido LCDR1, LCDR2, LCDR3 y HCVR comprende secuencias de aminoácido HCDR1, HCDR2, HCDR3, en donde LCDR1 es SEQ ID Ns 10, LCDR2 es SEQ ID Ns 11, LCDR3 es SEQ ID Ns 5, HCDR1 es SEQ ID Ns 12, HCDR2 es SEQ ID Ns 37y HCDR3 es SEQ ID Ns 38, en donde el anticuerpo CGRP humano une a CGRP humano. Composicion farmacéutica que lo comprende. Uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas. Fragmento de union a antígeno de dicho anticuerpo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35332310P | 2010-06-10 | 2010-06-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR081434A1 true AR081434A1 (es) | 2012-08-29 |
Family
ID=45096388
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110101867A AR081434A1 (es) | 2010-06-10 | 2011-05-31 | Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo |
Country Status (33)
| Country | Link |
|---|---|
| US (3) | US9073991B2 (es) |
| EP (2) | EP3318272B1 (es) |
| JP (2) | JP6021806B2 (es) |
| KR (1) | KR101489566B1 (es) |
| CN (2) | CN104292332B (es) |
| AR (1) | AR081434A1 (es) |
| AU (1) | AU2011265050B2 (es) |
| BR (1) | BR112012031501B1 (es) |
| CA (1) | CA2802102C (es) |
| CY (2) | CY1119789T1 (es) |
| DK (1) | DK2579894T3 (es) |
| EA (1) | EA022931B1 (es) |
| ES (2) | ES2930321T3 (es) |
| HR (1) | HRP20171992T1 (es) |
| HU (2) | HUE038135T2 (es) |
| IL (2) | IL222885B (es) |
| JO (1) | JO3330B1 (es) |
| LT (2) | LT2579894T (es) |
| LU (1) | LUC00112I2 (es) |
| ME (1) | ME02862B (es) |
| MX (2) | MX340999B (es) |
| NL (1) | NL300979I2 (es) |
| NO (2) | NO2579894T3 (es) |
| NZ (1) | NZ603607A (es) |
| PL (1) | PL2579894T3 (es) |
| PT (1) | PT2579894T (es) |
| RS (1) | RS56638B1 (es) |
| SG (1) | SG185648A1 (es) |
| SI (1) | SI2579894T1 (es) |
| TW (1) | TWI423818B (es) |
| UA (1) | UA109658C2 (es) |
| WO (1) | WO2011156324A1 (es) |
| ZA (1) | ZA201208996B (es) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1957106B2 (en) | 2005-11-14 | 2019-07-24 | Teva Pharmaceuticals International GmbH | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
| JP5537441B2 (ja) | 2008-03-04 | 2014-07-02 | ファイザー・リミテッド | 慢性疼痛を治療する方法 |
| KR101519192B1 (ko) | 2009-08-28 | 2015-05-11 | 리나트 뉴로사이언스 코프. | 칼시토닌 유전자-관련된 펩티드에 대해 지시된 길항제 항체의 투여에 의한 내장 통증의 치료 방법 |
| JO3330B1 (ar) * | 2010-06-10 | 2019-03-13 | Lilly Co Eli | الأجسام المضادة cgrp |
| DK2709663T3 (da) | 2011-05-20 | 2019-05-20 | Alderbio Holdings Llc | Anvendelse af anti-CGRP-antistoffer og antistoffragmenter til forebyggelse eller inhibering af fotofobi eller aversion mod lys hos individer med behov herfor, især migrænikere |
| SG10201604040PA (en) | 2011-05-20 | 2016-07-28 | Alderbio Holdings Llc | Anti-cgrp compositions and use thereof |
| US9855332B2 (en) | 2011-05-20 | 2018-01-02 | Alderbio Holdings Llc | Use of anti-CGRP antibodies and antibody fragments to treat diarrhea in subjects with diseases or treatments that result in elevated CGRP levels |
| KR102134088B1 (ko) | 2012-08-24 | 2020-07-14 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | Ror1 암을 치료하고 전이를 저해하는데 이용을 위한 항체와 백신 |
| US20170114122A1 (en) | 2015-10-23 | 2017-04-27 | Alderbio Holdings Llc | Regulation of glucose metabolism using anti-cgrp antibodies |
| SI3119431T1 (sl) | 2014-03-21 | 2024-06-28 | Teva Pharmaceuticals International Gmbh | Antagonistična protitelesa, usmerjena proti peptidu, povezanemu z genom za kalcitonin, in postopki za uporabo le-teh |
| US10556945B2 (en) * | 2014-03-21 | 2020-02-11 | Teva Pharmaceuticals International Gmbh | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
| MX382408B (es) | 2014-10-24 | 2025-03-13 | Merck Sharp & Dohme Llc | Coagonistas de los receptores de glucagón y de glp-1. |
| TWI595006B (zh) * | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗ｐｄ－１抗體類和使用彼等之方法 |
| JOP20200116A1 (ar) | 2015-04-24 | 2017-06-16 | Amgen Inc | طرق لعلاج أو الوقاية من الصداع النصفي |
| AR104847A1 (es) * | 2015-06-17 | 2017-08-16 | Lilly Co Eli | Formulación de anticuerpo anti-cgrp |
| WO2017074428A1 (en) * | 2015-10-30 | 2017-05-04 | Eli Lilly And Company | Anti-cgrp/anti-il-23 bispecific antibodies and uses thereof |
| CN105483091A (zh) * | 2015-12-29 | 2016-04-13 | 天津三箭生物技术股份有限公司 | 小鼠抗人Calcitonin单克隆抗体及分泌该单克隆抗体的杂交瘤细胞株 |
| KR20180091930A (ko) * | 2016-01-28 | 2018-08-16 | 일라이 릴리 앤드 캄파니 | Cgrp 항체 및 그의 용도 |
| CN108601833B (zh) | 2016-02-01 | 2022-11-15 | 伊莱利利公司 | 甲状旁腺激素-抗rankl抗体融合化合物 |
| US10688181B2 (en) | 2016-06-27 | 2020-06-23 | The Regents Of The University Of California | Cancer treatment combinations |
| PE20191148A1 (es) | 2016-09-23 | 2019-09-02 | Teva Pharmaceuticals Int Gmbh | Tratamiento de la migrana refractaria |
| MX2019003338A (es) | 2016-09-23 | 2019-09-26 | Teva Pharmaceuticals Int Gmbh | Tratamiento de cefalea en racimos. |
| US10766952B2 (en) | 2017-03-02 | 2020-09-08 | Beth Israel Deaconess Medical Center, Inc. | Methods for reducing migraine frequency in a subject in need thereof |
| TW201902926A (zh) * | 2017-05-03 | 2019-01-16 | 美商美國禮來大藥廠 | 抗cgrp／抗il-23雙特異性抗體及其用途 |
| US11426706B2 (en) | 2017-06-21 | 2022-08-30 | Cephalon, Inc. | Cation exchange chromatography wash buffer |
| TWI754772B (zh) * | 2017-09-06 | 2022-02-11 | 美商美國禮來大藥廠 | 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法 |
| JP7339262B2 (ja) | 2018-01-12 | 2023-09-05 | アムジェン インコーポレイテッド | Ｐａｃ１抗体及びその使用 |
| WO2019231800A1 (en) | 2018-05-31 | 2019-12-05 | Eli Lilly And Company | Anti-cgrp antibodies for treating menstrual-related migraines |
| US20210340230A1 (en) | 2018-08-22 | 2021-11-04 | Eli Lilly And Company | Anti-CGRP Antibodies For Treatment-Resistant Patients |
| CR20210373A (es) | 2019-01-08 | 2021-08-19 | H Lundbeck As | Tratamiento agudo y tratamiento rápido de la cefalea usando anticuerpos anti-cgrp |
| EP3744400A1 (en) * | 2019-05-28 | 2020-12-02 | Etablissement Français du Sang | Car-t cells targeting il-1rap and their use in acute myeloid leukemia (aml) |
| CN114127110B (zh) * | 2019-05-30 | 2022-07-01 | 山东博安生物技术股份有限公司 | 抗cgrp抗体及其应用 |
| CA3154522A1 (en) | 2019-10-15 | 2021-04-22 | Christopher Carl Frye | Recombinantly engineered, lipase/esterase-deficient mammalian cell lines |
| AU2020202454A1 (en) | 2020-04-06 | 2021-10-21 | H. Lundbeck A/S | Treatment of most bothersome symptom (MBS) associated with migraine using anti-CGRP antibodies |
| EP4301362A1 (en) | 2021-03-02 | 2024-01-10 | CGRP Diagnostics GmbH | Treatment and/or reduction of occurrence of migraine |
| AU2023223603A1 (en) | 2022-02-28 | 2024-08-22 | Tridem Bioscience Gmbh & Co Kg | A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN. |
| EP4570913A1 (en) * | 2022-08-11 | 2025-06-18 | Shanghai Junshi Biosciences Co., Ltd. | Anti-cgrp antibody and use |
| CN118271438B (zh) * | 2024-05-27 | 2024-08-30 | 上海宏成药业有限公司 | 抗cgrp抗体或其抗原结合片段及其用途 |
| CN119320450B (zh) * | 2024-12-13 | 2025-07-25 | 中国人民解放军军事科学院军事医学研究院 | 针对降钙素基因相关肽的抗体 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| JP3370324B2 (ja) * | 1991-04-25 | 2003-01-27 | 中外製薬株式会社 | ヒトインターロイキン−６受容体に対する再構成ヒト抗体 |
| JP4124480B2 (ja) * | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
| WO2005035753A1 (ja) | 2003-10-10 | 2005-04-21 | Chugai Seiyaku Kabushiki Kaisha | 機能蛋白質を代替する二重特異性抗体 |
| CA2603940A1 (en) * | 2005-04-08 | 2006-10-19 | Nancy Ulbrandt | Antibodies against mammalian metapneumovirus |
| EP1957106B2 (en) * | 2005-11-14 | 2019-07-24 | Teva Pharmaceuticals International GmbH | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
| WO2007076336A1 (en) * | 2005-12-22 | 2007-07-05 | Eli Lilly And Company | Treatment of migraine with anti-cgrp antibodies |
| JP5537441B2 (ja) * | 2008-03-04 | 2014-07-02 | ファイザー・リミテッド | 慢性疼痛を治療する方法 |
| CA2716799C (en) * | 2008-03-04 | 2018-05-22 | Pfizer Limited | Methods of treating inflammatory pain |
| JO3330B1 (ar) * | 2010-06-10 | 2019-03-13 | Lilly Co Eli | الأجسام المضادة cgrp |
-
2011
- 2011-05-31 JO JOP/2011/0177A patent/JO3330B1/ar active
- 2011-05-31 AR ARP110101867A patent/AR081434A1/es active IP Right Grant
- 2011-06-03 TW TW100119683A patent/TWI423818B/zh active
- 2011-06-07 DK DK11792989.3T patent/DK2579894T3/en active
- 2011-06-07 PL PL11792989T patent/PL2579894T3/pl unknown
- 2011-06-07 EA EA201270769A patent/EA022931B1/ru not_active IP Right Cessation
- 2011-06-07 CN CN201410474677.9A patent/CN104292332B/zh active Active
- 2011-06-07 SI SI201131359T patent/SI2579894T1/en unknown
- 2011-06-07 MX MX2012014480A patent/MX340999B/es active IP Right Grant
- 2011-06-07 RS RS20171265A patent/RS56638B1/sr unknown
- 2011-06-07 ES ES17201603T patent/ES2930321T3/es active Active
- 2011-06-07 JP JP2013514281A patent/JP6021806B2/ja active Active
- 2011-06-07 PT PT117929893T patent/PT2579894T/pt unknown
- 2011-06-07 US US13/154,538 patent/US9073991B2/en active Active
- 2011-06-07 ME MEP-2017-280A patent/ME02862B/me unknown
- 2011-06-07 KR KR1020127032068A patent/KR101489566B1/ko active Active
- 2011-06-07 WO PCT/US2011/039381 patent/WO2011156324A1/en not_active Ceased
- 2011-06-07 MX MX2016005150A patent/MX363209B/es unknown
- 2011-06-07 EP EP17201603.2A patent/EP3318272B1/en active Active
- 2011-06-07 HR HRP20171992TT patent/HRP20171992T1/hr unknown
- 2011-06-07 AU AU2011265050A patent/AU2011265050B2/en active Active
- 2011-06-07 SG SG2012084885A patent/SG185648A1/en unknown
- 2011-06-07 NO NO11792989A patent/NO2579894T3/no unknown
- 2011-06-07 CA CA2802102A patent/CA2802102C/en active Active
- 2011-06-07 NZ NZ603607A patent/NZ603607A/en unknown
- 2011-06-07 BR BR112012031501-3A patent/BR112012031501B1/pt active IP Right Grant
- 2011-06-07 ES ES11792989.3T patent/ES2656000T3/es active Active
- 2011-06-07 EP EP11792989.3A patent/EP2579894B1/en active Active
- 2011-06-07 HU HUE11792989A patent/HUE038135T2/hu unknown
- 2011-06-07 LT LTEP11792989.3T patent/LT2579894T/lt unknown
- 2011-06-07 CN CN201180028611.1A patent/CN102946905B/zh active Active
- 2011-07-06 UA UAA201212663A patent/UA109658C2/ru unknown
-
2012
- 2012-11-05 IL IL222885A patent/IL222885B/en active Protection Beyond IP Right Term
- 2012-11-28 ZA ZA2012/08996A patent/ZA201208996B/en unknown
-
2015
- 2015-06-04 US US14/730,270 patent/US9505838B2/en active Active
- 2015-11-02 IL IL242409A patent/IL242409B/en active IP Right Grant
-
2016
- 2016-06-28 JP JP2016127666A patent/JP6466883B2/ja active Active
- 2016-11-02 US US15/341,166 patent/US20170073403A1/en not_active Abandoned
-
2018
- 2018-01-18 CY CY20181100064T patent/CY1119789T1/el unknown
-
2019
- 2019-04-02 HU HUS1900020C patent/HUS1900020I1/hu unknown
- 2019-04-02 CY CY2019017C patent/CY2019017I1/el unknown
- 2019-04-05 NO NO2019017C patent/NO2019017I1/no unknown
- 2019-04-09 LU LU00112C patent/LUC00112I2/fr unknown
- 2019-04-11 NL NL300979C patent/NL300979I2/nl unknown
- 2019-04-12 LT LTPA2019011C patent/LTC2579894I2/lt unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR081434A1 (es) | Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo | |
| PE20210132A1 (es) | Anticuerpos anti-cd3 y usos de estos | |
| AR110203A1 (es) | Anticuerpos anti-tim-3 para combinación con anticuerpos anti-pd-1 | |
| PE20200011A1 (es) | ANTICUERPOS ANTI-PEPTIDO BETA AMILOIDE N3pGlu Y SUS USOS | |
| PE20141147A1 (es) | Anticuerpos a pcsk9 y usos de los mismos | |
| PE20200294A1 (es) | Anticuerpos que se unen especificamente a pd-1 y metodos de uso | |
| PE20191408A1 (es) | Proteinas de union a antigeno st2 | |
| PE20220218A1 (es) | Conjugados de anticuerpo-farmaco inhibidores de mcl-1 y sus metodos de uso | |
| PE20130817A1 (es) | Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos | |
| PE20241623A1 (es) | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos | |
| MX348581B (es) | Composicion farmaceutica para el tratamiento y/o prevencion de cancer. | |
| AR110017A1 (es) | Anticuerpos de pd-1 y usos de estos | |
| PE20181326A1 (es) | Anticuerpos que se unen especificamente a pd-1 y sus usos | |
| PE20141151A1 (es) | Proteinas de union al antigeno cd27l | |
| BR112012019098A2 (pt) | composição farmacêutica, combinação farmacêutica e método para o tratamento e/ou prevenção de um câncer e anticorpo | |
| AR071891A1 (es) | Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano) | |
| RU2015110981A (ru) | Комбинации и их применение | |
| PE20142243A1 (es) | Anticuerpos que se unen a ox40 y sus usos | |
| CO6230999A2 (es) | Anticuerpo anti-esclerostina | |
| PE20191079A1 (es) | Inmunoglobulinas y usos de estas | |
| NZ729158A (en) | Anti-ctla4 monoclonal antibody or antigen binding fragment thereof, medicinal composition and use | |
| NZ628943A (en) | Human antibodies to clostridium difficile toxins | |
| PE20170687A1 (es) | Proteinas de enlace a cd127 | |
| PE20130226A1 (es) | Anticuerpos hacia gdf8 humano | |
| PE20120340A1 (es) | Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y melfalan |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |